Top Markets
#1 Siacoin Siacoin +29.48%
#2 Official Trump Official Trump +25.53%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +19.32%
#4 EXOD EXOD +18.93%
#5 MowCat MowCat +18.23%
#6 Unit Pump Unit Pump +16.28%
#7 Pump.fun Pump.fun +16.28%
#8 Melania Meme Melania Meme +15.60%
#9 Mubarak Mubarak +14.72%
#10 Wrapped POL Wrapped POL +13.16%
Coin of the day
Siacoin Siacoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation

NYMX
Classifica tra le azioni #23483
Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm,... Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm, primarily focused on the discovery and advancement of medications for the aging population across Canada, the United States, Europe, and other international regions. The company's leading experimental compound is Fexapotide Triflutate (NX-1207), which has successfully concluded Phase III clinical trials for benign prostatic hyperplasia treatment. It has also completed Phase II trials for localized low-grade prostate cancer and is currently in preclinical studies for hepatocellular carcinoma. In addition to its drug pipeline, Nymox develops and markets diagnostic products. These include NicAlert and TobacAlert, tests that utilize urine or saliva samples to identify the use of tobacco products. The company further offers AlzheimAlert, a proprietary urine-based assay designed to aid healthcare professionals in diagnosing Alzheimer's disease. Alongside this diagnostic tool, Nymox is actively researching and developing therapeutic treatments for Alzheimer's disease. Founded in 1989, the company is headquartered in Nassau, the Bahamas.
Prezzo delle azioni
$0.977
Ultima sincronizzazione: 2023-08-11
Capitalizzazione di mercato
$72.98M
Variazione (1 giorno)
4.94%
Variazione (1 anno)
0.00%
Paese
BS
Scambia Nymox Pharmaceutical Corporation (NYMX)

Categoria

Healthcare
Utile per Nymox Pharmaceutical Corporation (NYMX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Nymox Pharmaceutical Corporation, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Nymox Pharmaceutical Corporation dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH